Uncategorized

BridgeBio’s achondroplasia pill shows ‘compelling’ growth and body proportionality benefit

Published

on

BridgeBio Pharma plans to file for approval in the third quarter. If granted, the oral drug could present a “highly differentiated” option over current achondroplasia therapies, according to Jefferies.

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version